Martin studied biotechnology in Braunschweig, Germany and cell and molecular biology in Rhode Island, USA. He subsequently obtained a PhD in Immunology from the Max Planck Institute of Immunology and Epigenetics in Freiburg, Germany. After successful completion of his PhD, Martin moved to Munich, Germany, joining the Helmholtz Zentrum to work on the establishment of a CRISPR/Cas9 screening pipeline in patient-derived xenograft models of acute leukemias. Within this project, Martin and Christian joined forces and established a multiplex cloning protocol for custom sgRNA libraries named CLUE. In 2020, Martin was recruited by AVA LifeScience to lead their R&D team, developing novel standards for FACS-based diagnostics.